Acquired cystic disease-associated renal cell carcinoma (ACD-RCC) is a common subtype of renal cell carcinoma (RCC) in end-stage renal disease (ESRD) patients. The current systematic review and meta-analysis was performed to evaluate the clinicopathological, and genetic characteristics of patients with ACD-RCC. A systematic search on three electronic databases including the Pubmed, Scopus, and Web of Science databases were performed until December 31, 2022. A meta-analysis was performed following the PRISMA 2020 Guidelines. Of 888 identified articles, full-text screening in 69 articles, there were 26 articles analyzed, with a total of 2314 tumors in 2199 patients, including 418 ACD-RCC tumors in 363 patients, 1340 clear cell RCC (ccRCC) tumors, 308 papillary RCC (pRCC) tumors. Most ACD-RCC patients were male (80.2%). All the ACD-RCC patients underwent prior dialysis with 148.2 months of mean dialysis duration. There were 8.7%, 3.4%, and 5.8% tumors at the T3-4 stage, N1 stage, and M1 stage, respectively. The mean overall survival of ACD-RCC patients was 39.6 months (95% CI, 26.6-52.5). Compared to ccRCC and pRCC, ACD-RCC patients had a longer duration of dialysis (MD: 103.5 and 31.77 months, respectively; 95% CI: [75.48; 131.53] and [0.95; 62.58], respectively), and a higher rate of multifocal tumors (MD: 3.46 and 2.45 tumors, respectively; 95% CI [1.71; 6.98] and [1.26; 4.79], respectively). Regarding genetic characteristics, chromosomes 3 and 16 were the 2 most frequent chromosomal aberrations. The missense mutation in (25%) and (18.75%) were the 2 most common gene mutations in ACD-RCC. In conclusion, the ACD-RCC subtype exhibited several distinct clinicopathological and genetic characteristics compared to others RCC subtypes. Further researchs are needed to assess the survival outcome and the genetic characteristics of this subtype.

中文翻译：

---

获得性囊性病相关肾细胞癌：系统评价和荟萃分析

获得性囊性疾病相关性肾细胞癌（ACD-RCC）是终末期肾病（ESRD）患者肾细胞癌（RCC）的常见亚型。目前的系统评价和荟萃分析旨在评估 ACD-RCC 患者的临床病理学和遗传特征。截至 2022 年 12 月 31 日，对 Pubmed、Scopus 和 Web of Science 数据库等三个电子数据库进行了系统检索。按照 PRISMA 2020 指南进行了荟萃分析。在888篇已识别文章中，对69篇文章进行全文筛选，分析了26篇文章，总共2199名患者的2314个肿瘤，其中363名患者的418个ACD-RCC肿瘤，1340个透明细胞RCC（ccRCC）肿瘤，308个乳头状肿瘤肾细胞癌 (pRCC) 肿瘤。大多数 ACD-RCC 患者为男性（80.2%）。所有 ACD-RCC 患者均接受过透析，平均透析时间为 148.2 个月。 T3-4期、N1期和M1期的肿瘤分别占8.7%、3.4%和5.8%。 ACD-RCC 患者的平均总生存期为 39.6 个月（95% CI，26.6-52.5）。与ccRCC和pRCC相比，ACD-RCC患者的透析时间更长（MD：分别为103.5个月和31.77个月；95％CI：分别为[75.48；131.53]和[0.95；62.58]），并且透析率较高多灶性肿瘤（MD：分别为 3.46 和 2.45 个肿瘤；95% CI 分别为 [1.71；6.98] 和 [1.26；4.79]）。关于遗传特征，3 号和 16 号染色体是 2 个最常见的染色体畸变。 (25%)和(18.75%)的错义突变是ACD-RCC中最常见的2种基因突变。总之，与其他 RCC 亚型相比，ACD-RCC 亚型表现出几种独特的临床病理学和遗传特征。需要进一步的研究来评估该亚型的生存结果和遗传特征。